| Fostamatinib Disodium | Rigel Pharms | ||
| 100,150 mg ; Tablet, Oral |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
| None |
Less Than 5
|
||
| None | None | ||
| TAVALISSE is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. | |||
|
Yes
| |||
| Tavalisse | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ****** ****** | ******* | *** ********* | *** ********* | *** ********* | *** ********* | ******* | *** ********* | ******* | ******* | *** ********* | ******* | *** ********* | *** ********* | *** ********* |
| ******** ** *,*-***************** ********* *** ***** **** | ******** ** *,*-***************** ********* *** ***** **** | ******** ** *,*-***************** ********* *** ***** **** | ******** ** *,*-***************** ********* *** ***** **** | ******** ** *,*-***************** ********* *** ***** **** | *** *********** ***** * ***** ************ ***** | ******** ** *,*-***************** ********* *** ***** **** | *** *********** ***** * ***** ************ ***** | (*********************) *********** ************ | ******** ** *,*-***************** ********* *** ***** **** | (*********************) *********** ************ | ******** ** *,*-***************** ********* *** ***** **** | ******** ** *,*-***************** ********* *** ***** **** | ******** ** *,*-***************** ********* *** ***** **** |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ****** ****** | *** / ********* | *** **, **** | ******* | ********* ******** | ** **, **** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|